FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3194632739> ?p ?o ?g. }

• W3194632739 endingPage "909.e6" @default.
• W3194632739 startingPage "909.e1" @default.
• W3194632739 abstract "High-dose post-transplantation cyclophosphamide (PTCy) is an effective platform for prevention of severe graft-versus-host disease (GVHD) after allogeneic bone marrow (BM) transplantation with mismatched unrelated donors (mMUDs). Previous studies evaluating PTCy with mMUDs favored BM allografts over peripheral blood stem cell transplantation (PBSCT) due to concerns that PBSCT may be associated with an increased risk of acute and chronic GVHD. In addition, haploidentical PBSCT is associated with high rates of cytokine release syndrome (CRS), which is another concern with mMUD PBSCT. This study was conducted to determine the feasibility and safety of using mMUD PBSCT with PTCy as GVHD prophylaxis. Patients who received mMUD PBSCT using a PTCy-based GVHD prophylaxis at Johns Hopkins Hospital as part of a prospective clinical trial of mMUD and non-first-degree relative haploidentical transplantation with PTCy (ClinicalTrials.gov identifier NCT01203722) were included. All patients underwent T cell-replete PBSCT between November 2012 and August 2020. Statistical analyses were performed using the Kaplan-Meier method and proportional subdistribution hazard regression model for competing risks. The 29 patients in the study had a median age of 54 years, with 10 patients (34%) age ≥60 years. Nineteen grafts (66%) were matched for 9/10 HLA loci, 6 (21%) were match for 8/10, and 4 (14%) were matched for 7/10. No primary or secondary graft failure occurred. The median time to neutrophil recovery (≥500/µL) was 17 days, and that to platelet recovery (≥20,000/µL) was 28 days. Full donor chimerism was achieved in all patients by day +60. The cumulative incidence (CuI) of grade II-IV acute GVHD at 180 days was 15% (90% confidence interval [CI], 3% to 26%). There were no cases of severe chronic GVHD, 3 cases of mild chronic GVHD, and 1 case of moderate chronic GVHD. The CuI of nonrelapse mortality (NRM) was 7% (90% CI, NA to 18%) at 1 year. Eighteen patients (62%) experienced mild CRS (grade 1-2), and 1 patient (3%) experienced severe CRS (grade 3-5). At 1 year, the CuI of relapse was 29% (90% CI, 8% to 50%), overall survival was 93% (90% CI, 85% to 100%), progression-free survival was 64% (90% CI, 46% to 88%), GVHD-free relapse-free survival was 41% (90% CI, 23% to 73%), and chronic GVHD-free relapse-free survival was 64% (90% CI, 46% to 88%). Our data indicate that mMUD PBSCT using PTCy-based GVHD prophylaxis is safe and feasible. All patients engrafted, and rates of NRM (7%) and acute GVHD (15%) at 1 year were low. There was only 1 case (3%) of severe CRS. Compared with previously published outcomes, mMUD PBSCT using PTCy-based GVHD prophylaxis has a safety and efficacy profile that may not be different from that of PBSCT from matched donors. These results further solidify that all patients who require blood or BM transplantation should be able to find an acceptable donor." @default.
• W3194632739 created "2021-08-30" @default.
• W3194632739 creator A5003078712 @default.
• W3194632739 creator A5008376801 @default.
• W3194632739 creator A5009906581 @default.
• W3194632739 creator A5015361329 @default.
• W3194632739 creator A5019799712 @default.
• W3194632739 creator A5026586699 @default.
• W3194632739 creator A5034547254 @default.
• W3194632739 creator A5035609080 @default.
• W3194632739 creator A5036664711 @default.
• W3194632739 creator A5047793815 @default.
• W3194632739 creator A5051833337 @default.
• W3194632739 creator A5056345529 @default.
• W3194632739 creator A5060234674 @default.
• W3194632739 creator A5065373363 @default.
• W3194632739 creator A5068593672 @default.
• W3194632739 creator A5071841968 @default.
• W3194632739 creator A5072199664 @default.
• W3194632739 creator A5078973630 @default.
• W3194632739 creator A5080825576 @default.
• W3194632739 creator A5089094849 @default.
• W3194632739 date "2021-11-01" @default.
• W3194632739 modified "2023-10-06" @default.
• W3194632739 title "Nonmyeloablative, HLA-Mismatched Unrelated Peripheral Blood Transplantation with High-Dose Post-Transplantation Cyclophosphamide" @default.
• W3194632739 cites W1491993932 @default.
• W3194632739 cites W1951884638 @default.
• W3194632739 cites W2002547051 @default.
• W3194632739 cites W2017000328 @default.
• W3194632739 cites W2019111335 @default.
• W3194632739 cites W2039334806 @default.
• W3194632739 cites W2044467556 @default.
• W3194632739 cites W2082708772 @default.
• W3194632739 cites W2084267226 @default.
• W3194632739 cites W2113899987 @default.
• W3194632739 cites W2116483603 @default.
• W3194632739 cites W2126021331 @default.
• W3194632739 cites W2148233118 @default.
• W3194632739 cites W2148995443 @default.
• W3194632739 cites W2166247867 @default.
• W3194632739 cites W2219528388 @default.
• W3194632739 cites W2335701371 @default.
• W3194632739 cites W2379365975 @default.
• W3194632739 cites W2532403292 @default.
• W3194632739 cites W2570187106 @default.
• W3194632739 cites W2590030902 @default.
• W3194632739 cites W2783728901 @default.
• W3194632739 cites W2786059331 @default.
• W3194632739 cites W2786706578 @default.
• W3194632739 cites W2808224767 @default.
• W3194632739 cites W2899657218 @default.
• W3194632739 cites W2955362686 @default.
• W3194632739 cites W2966397555 @default.
• W3194632739 cites W3049396522 @default.
• W3194632739 cites W3095258418 @default.
• W3194632739 cites W3097079471 @default.
• W3194632739 cites W3097498722 @default.
• W3194632739 cites W3134174123 @default.
• W3194632739 cites W3134918815 @default.
• W3194632739 cites W3173915704 @default.
• W3194632739 doi "https://doi.org/10.1016/j.jtct.2021.08.013" @default.
• W3194632739 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34425261" @default.
• W3194632739 hasPublicationYear "2021" @default.
• W3194632739 type Work @default.
• W3194632739 sameAs 3194632739 @default.
• W3194632739 citedByCount "5" @default.
• W3194632739 countsByYear W31946327392022 @default.
• W3194632739 countsByYear W31946327392023 @default.
• W3194632739 crossrefType "journal-article" @default.
• W3194632739 hasAuthorship W3194632739A5003078712 @default.
• W3194632739 hasAuthorship W3194632739A5008376801 @default.
• W3194632739 hasAuthorship W3194632739A5009906581 @default.
• W3194632739 hasAuthorship W3194632739A5015361329 @default.
• W3194632739 hasAuthorship W3194632739A5019799712 @default.
• W3194632739 hasAuthorship W3194632739A5026586699 @default.
• W3194632739 hasAuthorship W3194632739A5034547254 @default.
• W3194632739 hasAuthorship W3194632739A5035609080 @default.
• W3194632739 hasAuthorship W3194632739A5036664711 @default.
• W3194632739 hasAuthorship W3194632739A5047793815 @default.
• W3194632739 hasAuthorship W3194632739A5051833337 @default.
• W3194632739 hasAuthorship W3194632739A5056345529 @default.
• W3194632739 hasAuthorship W3194632739A5060234674 @default.
• W3194632739 hasAuthorship W3194632739A5065373363 @default.
• W3194632739 hasAuthorship W3194632739A5068593672 @default.
• W3194632739 hasAuthorship W3194632739A5071841968 @default.
• W3194632739 hasAuthorship W3194632739A5072199664 @default.
• W3194632739 hasAuthorship W3194632739A5078973630 @default.
• W3194632739 hasAuthorship W3194632739A5080825576 @default.
• W3194632739 hasAuthorship W3194632739A5089094849 @default.
• W3194632739 hasBestOaLocation W31946327391 @default.
• W3194632739 hasConcept C126322002 @default.
• W3194632739 hasConcept C141071460 @default.
• W3194632739 hasConcept C147483822 @default.
• W3194632739 hasConcept C188280979 @default.
• W3194632739 hasConcept C203014093 @default.
• W3194632739 hasConcept C207103383 @default.
• W3194632739 hasConcept C2776694085 @default.
• W3194632739 hasConcept C2776755627 @default.

• next